Pretreatment total lymphocyte count as a prognostic factor of survival in patients with recurrent cervical cancer after definitive radiation-based therapy: a retrospective study
3
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective This study evaluated the association between pretreatment total lymphocyte count (TLC) and overall survival (OS) in patients with recurrent cervical cancer. Methods We retrospectively reviewed 290 patients with recurrent cervical cancer with definite complete responses to either definitive radiotherapy or concurrent chemoradiotherapy between January 2009 and December 2022. The associations between pretreatment TLC and progression-free survival (PFS) and OS rates were evaluated. Results Ninety-three patients (32%) had a pretreatment TLC <1,000 cells/mm3. Patients with a pretreatment TLC <1,000 cells/mm3 had lower treatment response rates than their counterparts (P=0.045). The OS and PFS rates were significantly higher in patients with pretreatment TLC ≥1,000 cells/mm3 than in those with pretreatment TLC <1,000 cells/mm3 (10.74 vs. 3.89 months, P<0.0001; 8.32 vs. 4.97 months, P=0.042; respectively). Moreover, pretreatment TLC ≥1,000 cells/mm3 was identified as an independent prognostic factor for OS in both univariate analysis (hazard ratio [HR], 0.57; 95% conficence interval [CI], 0.44-0.74; P<0.001) and multivariate analysis (HR, 0.64; 95% CI, 0.47-0.86; P=0.003). However, TLC ≥1,000 cells/mm3 was identified as a prognostic factor for PFS only in univariate analysis (HR, 0.71; 95% CI, 0.51-0.99; P=0.043) but not in the multivariate analysis (HR, 0.81; 95% CI, 0.55-1.18; P=0.3). Conclusion Pretreatment TLC was associated with treatment response and was identified as an independent prognostic factor associated with the survival outcomes of patients with recurrent cervical cancer.
Abstract
Objective This study evaluated the association between pretreatment total lymphocyte count (TLC) and overall survival (OS) in patients with recurrent cervical cancer. Methods We retrospectively reviewed 290 patients with recurrent cervical cancer with definite complete responses to either definitive radiotherapy or concurrent chemoradiotherapy between January 2009 and December 2022. The associations between pretreatment TLC and progression-free survival (PFS) and OS rates were evaluated. Results Ninety-three patients (32%) had a pretreatment TLC <1,000 cells/mm3. Patients with a pretreatment TLC <1,000 cells/mm3 had lower treatment response rates than their counterparts (P=0.045). The OS and PFS rates were significantly higher in patients with pretreatment TLC ≥1,000 cells/mm3 than in those with pretreatment TLC <1,000 cells/mm3 (10.74 vs. 3.89 months, P<0.0001; 8.32 vs. 4.97 months, P=0.042; respectively). Moreover, pretreatment TLC ≥1,000 cells/mm3 was identified as an independent prognostic factor for OS in both univariate analysis (hazard ratio [HR], 0.57; 95% conficence interval [CI], 0.44-0.74; P<0.001) and multivariate analysis (HR, 0.64; 95% CI, 0.47-0.86; P=0.003). However, TLC ≥1,000 cells/mm3 was identified as a prognostic factor for PFS only in univariate analysis (HR, 0.71; 95% CI, 0.51-0.99; P=0.043) but not in the multivariate analysis (HR, 0.81; 95% CI, 0.55-1.18; P=0.3). Conclusion Pretreatment TLC was associated with treatment response and was identified as an independent prognostic factor associated with the survival outcomes of patients with recurrent cervical cancer.
참고문헌 (25)
- Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- "Hospitalbased cancer registry 2020" (2020)[URL]
- Bhatla N, "Cancer of the cervix uteri : 2021 update", Int J Gynaecol Obstet, 155(Suppl 1), pp.28~44 (2021)
- Fagundes H, "Distant metastases after irradiation alone in carcinoma of the uterine cervix", Int J Radiat Oncol Biol Phys, 24, pp.197~204 (1992)
- Eifel PJ, "Time course and outcome of central recurrence after radiation therapy for carcinoma of the cervix", Int J Gynecol Cancer, 16, pp.1106~1111 (2006)
- Poolkerd S, "Survival rate of recurrent cervical cancer patients", J Med Assoc Thai, 89, pp.275~282 (2006)
- Thanagumtorn K, "Survival rate of recurrent cervical carcinoma", J Med Assoc Thai, 95(Suppl 3), pp.S125~S130 (2012)
- Taguchi A, "High neutrophil-to-lymphocyte ratio is a predictor of short-term survival for patients with recurrent cervical cancer after radiation-based therapy", J Obstet Gynaecol Res, 47, pp.1862~1870 (2021)
- "NCCN clinical practice guidelines in oncology: cervical cancer version 1.2023" (2023)[URL]
- Rochet NM, "The role of complete blood cell count in prognosis-watch this space!", Oncol Hematol Rev, 8, pp.76~82 (2012)
- Mohme M, "Circulating and disseminated tumour cells-mechanisms of immune surveillance and escape", Nat Rev Clin Oncol, 14, pp.155~167 (2017)
- Shimizu K, "Immune suppression and reversal of the suppressive tumor microenvironment", Int Immunol, 30, pp.445~454 (2018)
- Wu ES, "Lymphopenia and its association with survival in patients with locally advanced cervical cancer", Gynecol Oncol, 140, pp.76~82 (2016)
- Feiya Shi, "Impact of hematologic toxicities during concurrent chemoradiation for cervical cancer", Obstetrics & Gynecology Science, 65(2), pp.176~187 (2022), 대한산부인과학회[DOI]
- Thiangphak E, "Pretreatment lymphocyte count as independent prognostic factor in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy", Int J Gynaecol Obstet, 159, pp.672~678 (2022)
- Inoue H, "Absolute lymphocyte count and Creactive protein-albumin ratio can predict prognosis and adverse events in patients with recurrent esophageal cancer treated with nivolumab therapy", Oncol Lett, 24, pp.257~ (2022)
- Zhang Y, "Normal absolute monocyte count in combination with normal", high absolute lymphocyte count at the time of relapse is associated with improved survival in patients with early relapsed acute myeloid leukemia, 2021, pp.39, 550~558
- Park JC, "Predictive value of peripheral lymphocyte counts for immune checkpoint inhibitor efficacy in advanced head and neck squamous cell carcinoma", Mol Clin Oncol, 13, pp.87~ (2020)
- Ida N, "Prognostic nutritional index as a predictor of survival in patients with recurrent cervical cancer", Mol Clin Oncol, 8, pp.257~263 (2018)
- Ittiamornlert P, "Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy", BMC Cancer, 19, pp.51~ (2019)
- Vasu S, "Williams hematology", pp.1204~ (2015), McGraw-Hill Education
- Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- Pardoll DM, "The blockade of immune checkpoints in cancer immunotherapy", Nat Rev Cancer, 12, pp.252~264 (2012)
- Maleki Vareki S, "Biomarkers of response to PD-1", PD-L1 inhibition, 2017, pp.116, 116~124
- Ho WJ, "Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas", J Immunother Cancer, 6, pp.84~ (2018)